Skip to main content

Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation

Buy Article:

$51.00 plus tax (Refund Policy)


Objective: Clozapine and risperidone were the first two antipsychotic drugs of a new class of agents for the pharmacotherapy of schizophrenia. It has been suggested that refractory schizophrenic patients who fail to respond to neither clozapine nor risperidone may respond to a combination/augmentation strategy of both medicaments.

Method: Three cases of individuals with unremittent schizophrenia treated via this combination are presented. Response was evaluated by clinical follow‐up and PANSS rating scale.

Results: Good clinical results with no noticeable adverse side effects, ascertained by a reduction from baseline scores of the Positive and Negative Syndrome Scale (PANSS) were obtained in all three patients.

Conclusions: The findings from this pilot study suggest this combination as a possible therapeutic approach for treating resistant schizophrenic patients.

Keywords: augmentation; clozapine; risperidone; schizophrenia

Document Type: Research Article


Publication date: 2000-04-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more